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diagnosed during oral contraceptive
use, 37 were thrombophilic. Of
65 women in the control group
who used oral contraceptives, ten
were thrombophilic. Among women
with thrombophilia, the risk of
developing DVT during the first year
of use, compared with prolonged use,
was increased 11-fold (95% CI
2-1-57-3).
Variation in susceptibility in each
woman is the key to finding an
explanation of why oral contraceptives
cause venous thrombosis.
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are pleased that 5 years after
the first studies, R M C Herings and
colleagues Quly 10, p 127)1 have
confirmed the difference in venous
thromboembolism risk between second
and third generation oral contra-
ceptives. The difference in risk is
highest among the yciungest women
who were exposed to sex steroids for
the first time, äs suggested in two of the
original studies.2·3
The investigators conclude that their
data point to an interaction between
types of oral contraceptives, and to an
unidentified susceptibility factor that
might be a prothrombotic mutation.
Although the exact mechanism by
which oral contraceptives cause venous
thrombosis is unknown, we feel that
progress was made by the finding of the
interaction between oral contraceptive
use and factor V Leiden in explaining
venous thrombosis.3·'' By analysing our
data for type of oral contraceptives, we
found that the age-adjusted relative risk
for the desogestrel-containing oral
contraceptive was 9-2 (95% CI
3-9-21-4) among non-carriers of factor
V Leiden mutation and 6-0 (1-9-19-0)
•niong carriers. This risk is, however,
in addition to the eight-fold increased
nsk of venous thrombosis for carriers
of the factor V Leiden mutation.
The risk for venous thrombosis is
highest during initial oral contraceptive
use, which suggests that some women
M« at immediate risk of thrombosis
when exposed to oral contraceptives.
This prompted us to re-analyse the
*»ta of the Leiden Thrombophilia
Study.' Women were classified
thrombophilic when they had
deficiencies of protein C, protein S, or
«ntithrombin, or mutations in factor V
Leiden or prothrombin 20210 A. The
*WK of developing deep-vein
»rombosis (DVT) was greatest in the
"W 6 months and the first year of use,
*»d women who developed venous
thrombosis during the early periods of
were likely to be thrombophilic.
Of 109 women with DVT objectively
Sir—R M C Herings and colleagues1
report a four-fold increased risk of
thromboembolic disease among users
of third-generation compared with
second-generation combined oral
contraceptives. This difference they
report äs highest among the youngest
women who used oral contraceptives
for the first time. We wonder whether
the investigators or other readers can
explain the very high rates of
thromboembolic disease in all users of
oral contraceptives in this study
compared with results from previous
studies.2
It was unclear to us whether
identification of "women with first
episodes of exclusive use of third—or
second—generation drugs" allowed
previous use of other vaneties of oral
contraceptives in that individual's
lifetime. In other words, were they all
new users of the combined oral
contraceptive (never previously
exposed), or had some used other types
of combined oral contraceptive in the
distant or recent past? This question is
obviously important in view of the
higher risk of thromboembolic disease
within the first year of use of combined
oral contraceptive.
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Authors' reply
Sir—First, we must apologise for and
correct several errors in our letter (see
Department of Error, p 1478).
Our study was limited to episodes of
first, exclusive use of third or second
generation oral contraceptives among
new users. Therefore, we first
converted all prescriptions of oral
contraceptives into episodes of
exclusive use, on the basis of the
numbers prescribed and dispensed
cycles. Most women had more than
one episode of contraceptive use, either
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because they stopped taking oral
contraceptives for a period of 1-2 years
or they switched to other methods of
contraception (<5%). To compare our
data with those of others we need to
extend our study to recurrent users. In
the total population, including new and
recurrent users, we saw 78 cases of
DVT during 209 706 person-years use
of second and third generation oral
contraceptives. The overall incidence
rate (new and recurrent users) was
3-7/10000 person-years with
5-5/10 000 person-years (49/88 295) for
users of third generation oral
contraceptives and 2-4/10000 person-
years (29/121 411) for users of second
generation oral contraceptives, giving a
crude relative risk of 2-3 (95%
CI 1-5-3-7). These rates and relative
risk corroborate the initial findings
cited by Vandenbroucke' and Walker2
and their colleagues. Our results are
also in line with Farmer and
colleagues'3 fmdings with respect to the
major potential confounding role of age
and calendar year. By contrast, we
limited the number of confounders by
restricting the exposure in our main
analysis to new, exclusive users of
second or third generation oral
contraceptives. We controlled for age
differences and date of initiation of
oral-contraceptive use by including age
and year of onset of use äs continuous
variables in our Poisson regression
models. Our findings clearly show
that the risk difference between third
and second generation oral
contraceptives is strengest among new,
healthy users of third generation oral
contraceptives.
Despite being able to follow up drug
use for most women since their
childhood to detect first use of oral
contraceptives, we cannot entirely
exclude past use of oral contraceptives.
However, any undetected past use
would lead us to underestimate the
relative risk we report. Differences
between new and recurrent use were
only recorded for third generation
contraceptive.(9-0/10000 vs 3-8/10000
person-years, and 2-4/10000 vs
2-4/10000 person-years for third and
second generation oral contraceptives).
Furthermore, the risk differences
between third and second generation
contraceptives declined from an eight-
fold to a two-fold risk difference over
time. Most thromboemboli were seen
during the first year of use and virtually
all thromboemboli occurred before the
end of the second year of use. The risk
in the first year of use was increased
compared with long-term use for both
second and third generation oral
contraceptives. These data are in line
with Kitty Bloemenkamp and
colleagues' conclusions, although we
have no data on genetic susceptibility.
Further research is necessary to
ascertain the mechanisms behind the
small but seemingly definite differences
in risk attributable to the second and
third generation oral contraceptives. A
noteworthy conclusion is that women
who have used these contraceptives for
more than l year without an episode of
DVT have safely run the gauntlet of
modestly raised risk.
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Sir—R M C Herings and co-workers'
present high relative risks of developing
venous thromboembolism (VTE)
among first users of third-generation
oral contraceptives compared with first
users of second generation oral
contraceptives. With an overall adjusted
estimate of 4-2, the relative risk seems
to be highest for women younger than
25 years (8-5), for duration of use of l
year or more (8-1), especially in the
absence of other disorders (14-1), and
is apparently independent of the type of
third generation progestagen used or
the oestrogen content of the
preparation. These findings were based
on 27 women who developed VTE
exposure to third generation and six
women exposed to second generation
oral contraceptives.
Several issues related to this analysis
should be addressed, apart from the
small number of cases. Although the
investigators 'repeatedly referred to a
base population of 450 000, it was
unclear how^ many women were
included in the calculations, and there
was no mention of the exact numbers
of non-cases in the cohort. The accrued
total exposure time was 54 939
woman-years over 10 years. Little
seems to have been done to validate the
data. The data> on exposure and
outcome were derived from different
sources, with exposure measured on a
regional basis and outcome on a
nationwide basis. Time periods were
not clearly defined in the exposure
database, for which data were
apparently collected retrospectively for
1986-89. Although implicitly stated, it
was not entirely clear that first users
actually became first users within the
time period assessed, nor whether the
definition of first user related to
continuous use. The issue of left-
censoring was unclear, and women
older than 16 years in 1986 may have
used oral contraceptives before the
database was established. Users of
second generation puls might therefore
have been misclassified äs first-time
users. Crude and adjusted risk ratios
showed little differences, despite large
differences in the age structures of
cases and non-cases by generation and
in other variables. Furthermore,
duration of use seemed not to have
been adjusted for.
We have shown the importance of
previous exposure history and duration
of use by use of a Cox's time-dependent
regression model on a dataset of the
transnational study, with additional
Information on lifetime use of oral
contraceptives (hazard ratio of third ra
second generation 0-79 [95% CI
0-50-1-26]).2 For first-time users,
taking into account duration of use, the
hazard ratio is 1-23 (0-70-20-07). For
previous users, the time-dependent
model adjusts for füll history of
exposure, giving a hazard ratio of 0-64
(0-48-0-83). Our results do not support
the Suggestion that there is an increased
risk of VTE in first-time users of third
generation oral contraceptives
compared with first-time users of
second generation oral contraceptives.
Data selection, small numbers of
cases, and not taking into account
duration of use are likely to outweigh
the potential influences of changing
prescribing patterns on the risk
estimates.
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